A retrospective analysis involving 44 articles and 5,322 hepatocellular carcinoma (HCC) patients treated with aPD-1/aPD-L1 monotherapy or combination therapies showed that patients with lower baseline Alpha-fetoProtein (AFP) levels exhibited higher disease control rate (DCR), as well as longer PFS and OS [20]. This evidence concerns the gene AFP and hepatocellular carcinoma.